Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Elutia Community
NasdaqCM:ELUT Community
1
Narratives
written by author
0
Comments
on narratives written by author
0
Fair Values set
on narratives written by author
Create a narrative
Elutia
Popular
Undervalued
Overvalued
Community Investing Ideas
Elutia
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
FDA Cleared EluPro Launch And Capacity Expansion Will Unlock Opportunity
Key Takeaways EluPro's FDA clearance and market entry against Medtronic's TYRX could drive significant revenue growth in the antibiotic-eluting envelope space. Strategic partnerships, expanded capacity, and production efficiencies are expected to enhance market penetration, lower costs, and boost margins.
View narrative
US$7.50
FV
72.9% undervalued
intrinsic discount
48.32%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
8 days ago
author updated this narrative
Your Valuation for
ELUT
ELUT
Elutia
Your Fair Value
US$
Current Price
US$2.03
72.1% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-49m
175m
2015
2018
2021
2024
2025
2027
2030
Revenue US$175.0m
Earnings US$35.6m
Advanced
Set Fair Value